Ascendis Pharma A/S (ASND)

270.56 -0.56 (-0.21%) USD  |  NASDAQ  |  Sep 04, 16:00
271.49 +0.93 (+0.34%) After-Hours: 20:00
More

Ascendis Pharma SG&A Expense (TTM) : 662.10M for June 30, 2026

SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for ASND.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical SG&A Expense (TTM) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 662.10M
March 31, 2026 582.56M
December 31, 2025 519.00M
September 30, 2025 446.44M
June 30, 2025 390.63M
March 31, 2025 348.62M
December 31, 2024 314.76M
September 30, 2024 298.00M
June 30, 2024 290.48M
March 31, 2024 286.97M
December 31, 2023 285.88M
September 30, 2023 274.77M
June 30, 2023 266.65M
March 31, 2023 250.38M
December 31, 2022 232.18M
September 30, 2022 229.71M
June 30, 2022 214.93M
March 31, 2022 197.33M
December 31, 2021 188.99M
September 30, 2021 158.13M
June 30, 2021 132.31M
March 31, 2021 112.61M
December 31, 2020 87.48M
September 30, 2020 82.04M
June 30, 2020 72.67M
Date Value
March 31, 2020 62.08M
December 31, 2019 54.19M
September 30, 2019 44.84M
June 30, 2019 41.62M
March 31, 2019 35.53M
December 31, 2018 29.41M
September 30, 2018 24.67M
June 30, 2018 20.10M
March 31, 2018 17.43M
December 31, 2017 15.25M
September 30, 2017 13.98M
June 30, 2017 13.59M
March 31, 2017 13.05M
December 31, 2016 12.71M
September 30, 2016 12.97M
June 30, 2016 11.57M
March 31, 2016 10.93M
December 31, 2015 7.721M
September 30, 2015 6.879M
June 30, 2015 7.389M
March 31, 2015 5.017M
December 31, 2014 5.017M
September 30, 2014 2.813M
June 30, 2014 1.534M
March 31, 2014 1.534M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Evaxion AS 4.527M
BioMarin Pharmaceutical, Inc. 1.368B
Genmab A/S 726.50M
Zealand Pharma A/S 78.53M
Cellectis SA 21.32M